mineralocorticoid receptor antagonists

6 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyClinical Trial Meta-AnalysisRace

Efficacy and Safety of Mineralocorticoid Receptor Antagonists Across Racial Groups in Heart Failure: Insights From a Large-Scale Individual Participant Data Meta-Analysis

By MedXY|Aug 8, 2026

This meta-analysis of four placebo-controlled trials reveals no significant difference in the efficacy and safety of mineralocorticoid receptor antagonists between Black and non-Black patients with heart failure, regardless of heart failure

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

mineralocorticoid receptor antagonists

Latest news

Efficacy and Safety of Mineralocorticoid Receptor Antagonists Across Racial Groups in Heart Failure: Insights From a Large-Scale Individual Participant Data Meta-Analysis

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

Normalising Renin After Medical Therapy for Primary Aldosteronism May Lower Cardiovascular Risk — But RCTs Are Needed

Reassessing the Role of Steroidal Mineralocorticoid Receptor Antagonists in Dialysis Patients: Safety and Efficacy Insights from a Systematic Review and Meta-Analysis

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

Spironolactone in Chronic Haemodialysis Patients: Insights from the ALCHEMIST Trial and Updated Meta-Analysis